Nautilus Biotechnology (NASDAQ:NAUT) Major Shareholder Ah Equity Partners Bio Ii, L.L Sells 5,000,000 Shares

Posted by Geri Gentry on Jun 5th, 2026

Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Free Report) major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total value of $11,750,000.00. Following the completion of the transaction, the insider owned 971,885 shares in the company, valued at $2,283,929.75. The trade was a 83.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Nautilus Biotechnology Price Performance

Shares of NASDAQ NAUT opened at $2.68 on Friday. The stock has a market capitalization of $340.57 million, a P/E ratio of -5.83 and a beta of 0.75. The business’s 50 day moving average is $2.90 and its two-hundred day moving average is $2.46. Nautilus Biotechnology, Inc. has a 1-year low of $0.62 and a 1-year high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Guggenheim increased their price target on Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Nautilus Biotechnology presently has an average rating of “Hold” and a consensus target price of $4.00.

View Our Latest Stock Report on NAUT

Institutional Investors Weigh In On Nautilus Biotechnology

A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC grew its position in shares of Nautilus Biotechnology by 19.6% during the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock valued at $46,000 after acquiring an additional 3,849 shares during the period. Bridgeway Capital Management LLC grew its position in shares of Nautilus Biotechnology by 4.0% during the 4th quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock valued at $254,000 after acquiring an additional 5,000 shares during the period. Renaissance Technologies LLC grew its position in shares of Nautilus Biotechnology by 2.2% during the 1st quarter. Renaissance Technologies LLC now owns 265,700 shares of the company’s stock valued at $1,031,000 after acquiring an additional 5,800 shares during the period. Geode Capital Management LLC lifted its stake in Nautilus Biotechnology by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock valued at $1,094,000 after buying an additional 7,307 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. purchased a new position in Nautilus Biotechnology in the 1st quarter valued at about $48,000. 50.71% of the stock is currently owned by institutional investors and hedge funds.

Nautilus Biotechnology Company Profile

(Get Free Report)

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.